Traditionally, doctors and clinicians thought diseases that affect muscles or bones affected those areas specifically. For example, bone diseases only affect bones, or muscle diseases only concerned muscles. But recent evidence supports the notion that bones and muscles are more interconnected than previously thought…
Lees meer..

The U.S. Food and Drug Administration sent a letter to companies and a wide range of other key stakeholders detailing the agency’s concern over cargo and warehouse thefts of FDA-regulated products. The products stolen have included prescription and over-the counter medicines, medical devices, and infant formula…
Lees meer..

Bloomberg BusinessWeek: The health overhaul legislation will likely cost drugmakers $25 billion more than the $80 billion the industry anticipated when it agreed to back the Democratic-led effort, according to Wall Street analysts. “The extra costs will come from expanding drug rebates through Medicaid, the U.S. insurance program for the poor, [Leerink Swann & Co executive] John L…
Lees meer..

The New York Times: AstraZeneca has settled a case and agreed to pay $520 million after federal investigations into its marketing practices for a schizophrenia drug, Seroquel. The announcement came Tuesday from Attorney General Eric Holder…
Lees meer..

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced that its first Phase 2 trial with MYDICAR® for the treatment of advanced heart failure has met the prospectively defined safety and efficacy endpoints for the trial as defined in the Phase 2 clinical trial protocol…
Lees meer..

Ceregene, Inc., a biopharmaceutical company, announced that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson’s disease patients…
Lees meer..

Kiadis Pharma provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor…
Lees meer..

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the “Company”) announced that the North Central Cancer Treatment Group (”NCCTG”) plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast (”mTNBC”) cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2…
Lees meer..

A review and analysis of previously published studies finds that patients, research participants and journal readers believe financial relationships between medicine and industry should be disclosed, in part because those financial ties may influence research and clinical care, according to a report in the April 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals…
Lees meer..

GeNOsys, Inc. (OTCBB: GNYS) announced they are sponsoring a Phase I safety trial in collaboration with Nitric Solutions Inc. GeNOsys will be testing their patented nitric oxide generator and nitric oxide producing formula for safety and effectiveness in treating disease…
Lees meer..